Staar Surgical
Staar Surgical Company, commonly referred to as Staar, is a leading innovator in the ophthalmic medical device industry, headquartered in the United States. Founded in 1982, the company has made significant strides in the development of advanced intraocular lenses (IOLs) and minimally invasive surgical technologies, particularly for cataract and refractive procedures. With a strong presence in key markets across North America, Europe, and Asia, Staar Surgical is renowned for its proprietary lens designs, including the Visian ICL, which offers unique benefits for patients with myopia and hyperopia. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as FDA approvals and expanding its product portfolio to enhance patient outcomes. Staar continues to set benchmarks in the ophthalmic sector, driven by its dedication to innovation and quality.
DitchCarbon Score
How does Staar Surgical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Staar Surgical's score of 36 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Staar Surgical's reported carbon emissions
In 2023, Staar Surgical reported total carbon emissions of approximately 1,542,000 kg CO2e, comprising 59,000 kg CO2e from Scope 1 and about 1,483,000 kg CO2e from Scope 2 emissions. This marks an increase from 2022, when total emissions were about 1,301,000 kg CO2e, with Scope 1 at 63,000 kg CO2e and Scope 2 at approximately 1,238,000 kg CO2e. Staar Surgical has set ambitious climate commitments, aiming for net zero emissions by 2050 for both Scope 1 and Scope 2 emissions. In the near term, the company has achieved significant reductions through its mobility and commuting programme, resulting in over 80% reduction in greenhouse gas contributions from 2022 to 2023. Additionally, they have targeted a 10% reduction in energy intensity from 2022 to 2023, measured in kWh per $1,000 USD in sales. These initiatives reflect Staar Surgical's commitment to sustainability and reducing its carbon footprint in the medical device industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 53,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 948,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Staar Surgical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
